Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Nverify (what is YN ?)
Infobox references
Chemical compound
Fasoracetam is a research chemical of the racetam family.[3] It is a putative nootropic that failed to show sufficient efficacy in clinical trials for vascular dementia. It is currently being studied for its potential use for attention deficit hyperactivity disorder.[2][4]
Fasoracetam appears to agonize all three groups of metabotropic glutamate receptors and has improved cognitive function in rodent studies.[5] It is orally bioavailable and is excreted mostly unchanged via the urine.[6]
Fasoracetam was discovered by scientists at the Japanese pharmaceutical company Nippon Shinyaku, which brought it through Phase 3 clinical trials for vascular dementia, and abandoned it due to lack of efficacy.[5][7]
Scientists at Children's Hospital of Philadelphia led by Hakon Hakonarson have studied fasoracetam's potential use in attention deficit hyperactivity disorder.[5] Hakonarson's company neuroFix tried to bring the drug to market for this use; neuroFix acquired Nippon Shinyaku's clinical data as part of its efforts.[7][8] neuroFix was acquired by Medgenics in 2015.[8] Medgenics changed its name to Aevi Genomic Medicine in 2016.[9]
Clinical trials in adolescents with ADHD who also have mGluR mutations started in 2016.[8] While Fasoracetam may be effective in the treatment of ADHD in people with specific mGluR mutations, these represent around 10% of total ADHD cases, and Fasoracetam is likely ineffective in all other cases.[10][11] Studies showing improvements in cognitive function from fasoracetam have exclusively been done on rodents.[10]
^FDA/NIH Substance registration system. Page accessed March 21, 2016
^ ab"Drug Profile Fasoracetam".
^"5-oxo-D-prolinepiperidinamide monohydrate - Compound Summary". Retrieved 21 July 2013.
^"Recommended INN List 40" (PDF). WHO Drug Information. 12 (2). 1998.
^ abcConnolly, J; Glessner, J; Kao, C; Elia, J; Hakonarson, H (2015). "ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder". Ther Innov Regul Sci. 49 (5): 632–642. doi:10.1177/2168479015599811. PMC 4564067. PMID 26366330.
^Malykh, AG; Sadaie, MR (12 February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders". Drugs. 70 (3): 287–312. doi:10.2165/11319230-000000000-00000. PMID 20166767. S2CID 12176745.
^ abMoskowitz, D. H. (2017). Finding the Genetic Cause and Therapy for ADHD, Autism and 22q. BookBaby (self published). ISBN 9781483590981.
^ abcSharma, B. (7 October 2016). "Medgenics: NFC-1 Could Be A Key Future Revenue Driver". Seeking Alpha.
^"Press Release: Medgenics, Inc. Announces Name Change to Aevi Genomic Medicine, Inc". Aevi via MarketWired. 16 December 2016.
^Tardner, P (2020-09-09). "Fasoracetam as a treatment for ADHD: A systematic review of available clinical data". International Journal of Environmental Science & Technology.
Fasoracetam is a research chemical of the racetam family. It is a putative nootropic that failed to show sufficient efficacy in clinical trials for vascular...